Ashlyna Kit
Product Images NDC 68462-646

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Ashlyna (NDC 68462-646). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ethinylestradiol

Chemical structure diagram of the active ingredients in Ashlyna, specifically Levonorgestrel and Ethinyl Estradiol, showing their steroidal molecular framework.*

FDA Label Image

Figure1

A bar graph depicting the percentages of bleeding and/or spotting versus bleeding alone over four cycles (Cycle 1: Days 1-91, Cycle 2: Days 92-182, Cycle 3: Days 183-273, Cycle 4: Days 274-364). Each cycle shows data for two time frames: ≥7 days and ≥20 days, with bleeding and/or spotting percentages consistently higher than bleeding alone. Sample sizes decrease from N=758 in Cycle 1 to N=446 in Cycle 4.*

FDA Label Image

Levonorgestrel

Chemical structure diagram of the active ingredient from the Ashlyna kit, showing the molecular framework typical of steroid hormones.*

FDA Label Image

Blistercard

Ashlyna kit packaging label showing a multi-week blister layout with circles representing tablet placement for 13 weeks. Each weekly row is labeled with days Sunday through Saturday or Friday and Saturday, organized in a sequential flow. The label displays the active ingredients Levonorgestrel 0.15 mg, Ethinyl Estradiol 0.03 mg, and Ethinyl Estradiol 0.01 mg. The Glenmark Pharmaceuticals Inc. logo is visible at the bottom right corner of each section.*

FDA Label Image

Figure 2

An illustration showing the effectiveness of various birth control methods arranged vertically by pregnancy rates per 100 women per year. At the top with fewer than 1 pregnancy are implants, injections, intrauterine devices, and sterilization. Below are birth control pills, skin patch, and vaginal rings with hormones. Further down are condoms and diaphragm. Near the bottom are no sex during fertile days, spermicide, and withdrawal. At the bottom with the most pregnancies is no birth control.*

FDA Label Image

Figure2

A forest plot chart showing effect estimates from various studies comparing contraceptive use versus never use. The x-axis represents effect estimates ranging from -1.50 to 2.00. The plot includes odds ratios (OR), relative risks (RR), and hazard ratios (HR) with 95% confidence intervals depicted as horizontal lines and points for each study, including the NICHD Women’s Care Study, French E3N cohort, Shanghai Women’s Health Study, Nurses' Health Study II, Oxford Family Planning Study, and Danish Sex Hormone Register Study.*

FDA Label Image

Logo (Image 01)

Packaging label for Ashlyna, a kit containing levonorgestrel and ethinyl estradiol tablets with strengths of 0.15 mg/0.03 mg and 0.01 mg respectively. The kit includes 2 extended-cycle tablet dispensers, each with 91 tablets, from Glenmark Pharmaceuticals Inc., USA. The label includes storage instructions and a barcode.*

FDA Label Image

Logo (Image 02)

Ashlyna kit with Levonorgestrel and Ethinyl Estradiol Tablets, USP 0.15 mg/0.03 mg and Ethinyl Estradiol Tablets, USP 0.01 mg. The label shows 1 extended-cycle tablet dispenser containing 91 tablets. Manufactured by Glenmark Pharmaceuticals Limited and for Glenmark Pharmaceuticals Inc., USA. The label includes dosage and storage instructions, a barcode, and Glenmark logo.*

FDA Label Image

Logo

FDA Label Image

Logo1

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.